For healthcare professionals only
Welcome to the CKD and T2D: Developments in the management of DKD resource hub for events and learning materials. Here you can find details of upcoming webinars that may be relevant to your clinical practice, as well as access a range of on-demand videos, podcasts and downloadable resources to support you in your ongoing education and development.
Throughout this website, the events and materials will focus on the role of Kerendia▼ (finerenone) in the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) in adults with type 2 diabetes. This website will be updated with additional materials on a regular basis, so do bookmark this site and revisit us. We hope you find these resources useful in your everyday clinical practice.
Reporting adverse events and quality complaints
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to:
Tel: 01182063500 or email: [email protected]
PP-KER-GB-0192 | September 2022
Welcome to the CKD and T2D: Developments in the management of DKD resource hub for events and learning materials. Here you can find details of upcoming webinars that may be relevant to your clinical practice, as well as access to a range of on-demand videos, podcasts and downloadable resources to support you in your ongoing education and development.
Throughout this website, the events and materials will focus on the role of Kerendia▼ (finerenone) in the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) in adults with type 2 diabetes. This website will be updated with additional materials on a regular basis, so do bookmark this site and revisit us. We hope you find these resources useful in your everyday clinical practice.
Philip Kalra graduated from Cambridge University and is Professor of Nephrology in Salford and the University of Manchester, Consultant Nephrologist since 1995. He has major research focus on renovascular disease, cardiovascular disease in CKD, CKD progression and iron use in CKD. He is Director of Research in the Northern Care Alliance, the trust encompassing Salford Royal. He was Academic Vice President of the UK Renal Association 2016-19, Chair of the UK Kidney Research Consortium during this time and was Chair of the NIHR CRN Renal Disorders group from 2010 until 2018. He has been involved in the development of several large UK clinical trials in nephrology and cardiology, including the ASTRAL, PIVOTAL and IRONMAN trials, and he has played a role in amalgamating Cardio- Renal education and research within the UK.
Kieran McCafferty is a Consultant Nephrologist and Honorary Senior Lecturer at Barts Health NHS trust and Queen Mary University London. He has clinical and research interests in cardiorenal disease and diabetic kidney disease . He was the UK principal investigator for the the phase 3 FIDELIO-DKD study.
Reporting adverse events and quality complaints
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to:
Tel: 01182063500 or email: [email protected]
PP-KER-GB-0175 | July 2022
The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2022 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.
